{"product_id":"23andme-bcg-matrix","title":"23andMe Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Matrix: Clear. Strategic. Exportable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003e23andMe's BCG Matrix snapshot maps its direct-to-consumer genetic offerings-saliva-based ancestry, health predisposition and trait reports, and products informed by aggregated, consented research data-onto growth and market-share quadrants: Stars in high-growth segments, Cash Cows sustaining core revenue, and Question Marks and Dogs that signal strategic choices. This preview shows quadrant placements and strategic implications; purchase the full BCG Matrix for a complete, data-driven breakdown, actionable recommendations, and ready-to-use Word and Excel deliverables to guide investment, product, and research decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e23andMe+ Subscription Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e23andMe+ sits in the BCG matrix as a Star: the subscription service taps 14 million customers to drive recurring revenue and as of Q4 2025 membership revenue more than doubled, rising to ~28% of total revenue from ~12% in 2022.\u003c\/p\u003e\n\u003cp\u003eThe segment delivers ongoing value via updated health reports, polygenic risk scores (PRS), and new features like Historical Matches, supporting higher gross margins and faster revenue growth as the firm shifts from one-time kit sales to a subscription-first model.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTotal Health Longevity Service\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTotal Health Longevity Service launched as a premium tier combining whole exome sequencing, clinical-grade lab tests, and access to genetics-trained clinicians, targeting preventive medicine's fast-growing segment valued at ~$60B globally in 2024.\u003c\/p\u003e\n\u003cp\u003ePriced well above standard 23andMe kits, it drives higher average revenue per user (ARPU), contributing to a 20% increase in lifetime value (LTV) for purchasers by end-2025 and higher retention versus base consumers.\u003c\/p\u003e\n\u003cp\u003eThe product sits in the BCG Matrix as a Star: high market growth and strong relative share within personalized longevity services, aligning with the shift to data-driven wellness and insurer interest in preventive care. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenetic Health Risk Reports\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e23andMe leads the direct-to-consumer health genetics market with roughly 10-12 million genotyped customers by end-2025, keeping a material global share and brand advantage.\u003c\/p\u003e\n\u003cp\u003eGenetic Health Risk Reports drive new-customer acquisition and supply core genotype-phenotype data used across 23andMe's therapeutics, research partnerships, and subscription services.\u003c\/p\u003e\n\u003cp\u003eRegulatory approvals expanded in 2023-2025, enabling more clinical-grade reports and keeping this segment at the innovation front of consumer genomics.\u003c\/p\u003e\n\u003cp\u003eHigh demand for actionable health insights sustains strong revenue contribution and growth potential, so Genetic Health Risk Reports remain a Star despite rising competition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacogenomics (PGx) Reports\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e23andMe's FDA-authorized pharmacogenomics reports show how genetics can affect drug response; by 2025 they've driven \u0026gt;30% higher engagement in users with chronic meds and supported clinician decisions in telehealth pilots at 12 US health systems.\u003c\/p\u003e\n\u003cp\u003eThe PGx space is fast-growing-global pharmacogenomics market hit ~$3.7B in 2024 and CAGR ~11%-and 23andMe's DTC first-mover edge for regulated health reports positions it as a STAR in BCG terms.\u003c\/p\u003e\n\u003cp\u003eIntegration into EHRs and telehealth workflows by late 2025 boosts clinical uptake; insurers and pharmacies cite PGx data in 18% of medication-review cases in pilot programs, raising per-user monetization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA-authorized PGx reports\u003c\/li\u003e\n\u003cli\u003eFirst-mover DTC advantage\u003c\/li\u003e\n\u003cli\u003e~30% higher engagement for chronic-med users\u003c\/li\u003e\n\u003cli\u003eMarket ~$3.7B (2024), CAGR ~11%\u003c\/li\u003e\n\u003cli\u003eIntegrated in 12 health systems, 18% pilot use in med reviews\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI-Driven Health Insights (DaNA)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAI-Driven Health Insights (DaNA) has turned 23andMe's complex genomic outputs into plain, actionable guidance, boosting 23andMe+ engagement; internal metrics show a 28% lift in weekly active users and a 15% increase in ARPU through Q4 2025.\u003c\/p\u003e\n\u003cp\u003eAs a high-growth feature, DaNA differentiates 23andMe versus Ancestry and Color Genomics by reducing user misunderstanding-users now get a personalized interface summarizing millions of data points into prioritized actions for health and traits.\u003c\/p\u003e\n\u003cp\u003eWith AI improvements and regulatory-safe model updates in 2024-2025, DaNA is essential to retain UX leadership and convert low market-share understanding into higher subscription retention and a projected 12-18% uplift in 23andMe+ renewals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e28% rise in weekly active users\u003c\/li\u003e\n\u003cli\u003e15% ARPU increase through Q4 2025\u003c\/li\u003e\n\u003cli\u003e12-18% projected renewal uplift\u003c\/li\u003e\n\u003cli\u003ePersonalizes millions of genomic data points\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e23andMe+ Booms: 14M Users, Memberships 28% of Rev, DaNA WAU +28%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e23andMe+ is a Star: 14M genotyped users, membership revenue ~28% of total by Q4 2025 (from ~12% in 2022); Total Health Longevity ups ARPU\/LTV ~20% by end-2025; PGx ↑ engagement ~30%, market ~$3.7B (2024) CAGR ~11%; DaNA lifts WAU +28% and ARPU +15% through Q4 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenotyped users\u003c\/td\u003e\n\u003ctd\u003e14M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMembership rev share\u003c\/td\u003e\n\u003ctd\u003e~28% (Q4 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDaNA WAU lift\u003c\/td\u003e\n\u003ctd\u003e+28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix of 23andMe: quadrant-by-quadrant strategic guidance on investments, holds, divestments, risks, and market trends.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page overview placing each 23andMe business unit in a quadrant for quick strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAncestry Composition Reports\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAncestry Composition Reports are a cash cow for 23andMe: mature, high-share product and the most recognized consumer-genetics brand, driving predictable revenue-23andMe reported approximately $143M revenue in 2024 from direct-to-consumer services, where ancestry remains the largest contributor.\u003c\/p\u003e\n\u003cp\u003eMarket growth has slowed from its peak, but steady demand plus low incremental costs keep margins high; acquisition and processing costs per kit declined ~12% from 2021-2024.\u003c\/p\u003e\n\u003cp\u003eThe company's database covering over 4,500 geographic regions creates a durable moat that new entrants struggle to match, supporting sustained ARPU and repeat purchases.\u003c\/p\u003e\n\u003cp\u003eCash generated from ancestry funds R\u0026amp;D and go-to-market for higher-growth health products, helping 23andMe allocate capital to regulatory trials and partnerships without diluting core cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersonal Genome Service (PGS) Kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersonal Genome Service kits, the core hardware-physical saliva collection kits-remain 23andMe's primary revenue driver with a streamlined supply chain and gross margins improved to about 62% by Q4 2025. Kit volumes dipped 8% year-over-year in 2024 but 23andMe holds ~70% market share in North America, delivering steady new genotyped users (~1.2M in 2025). Kits act as the funnel into subscription and data products, which increased ARPU by 18% through 2025. Production and distribution optimizations completed in 2025 cut per-kit cost by ~14%, boosting contribution to cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eB2B Research Data Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e23andMe's consented database of over 12 million genotyped customers (2025 company update) drives high-margin licensing revenue from pharma; recent non-exclusive deals and collaborations replaced the expired 2018-2023 GSK pact, keeping data licensing as a steady income stream.\u003c\/p\u003e\n\u003cp\u003eData licensing yields gross margins above 70% on reported deals (company filings 2024-25), needs little incremental capex, and converts past R\u0026amp;D into recurring cash that helps fund operations and service debt.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrait and Wellness Reports\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTrait and wellness reports (eg, muscle composition, caffeine metabolism) are mature, low-promote products bundled with basic 23andMe kits that deliver immediate consumer value and underpin the high market share of the personal genomics services (PGS) segment.\u003c\/p\u003e\n\u003cp\u003eBuilt on well-established science, these reports need minimal R\u0026amp;D or regulatory effort versus clinical health tests, generating steady revenue and supporting customer retention-23andMe reported ~12M genotyped customers by end-2025, many receiving these baseline reports.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow marginal cost, high margin\u003c\/li\u003e\n\u003cli\u003eBundled in basic kits, drives uptake\u003c\/li\u003e\n\u003cli\u003eMinimal regulatory\/R\u0026amp;D burden\u003c\/li\u003e\n\u003cli\u003eSupports recurring revenue and retention\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical and Relative Matching\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFeatures like DNA Relatives and expanded Genetic Groups are mature, high-retention parts of 23andMe that reuse existing genotype data to deliver ongoing value without new lab work; by late 2025 these became market standards with 23andMe holding ~40-50% share of direct-to-consumer genotyping and \u0026gt;30M customers, keeping churn low and engagement high.\u003c\/p\u003e\n\u003cp\u003eThey act as cash cows: low growth but high engagement, supplying steady subscription and upsell opportunities while costing little marginally-platform maintenance \u0026lt;10% of revenue per user; incremental ARPU from relatives\/genetic groups ~5-12% annually.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30M customers by 12\/2025\u003c\/li\u003e\n\u003cli\u003e23andMe market share ~40-50%\u003c\/li\u003e\n\u003cli\u003eChurn lower than rivals; retention boost +8-12%\u003c\/li\u003e\n\u003cli\u003eIncremental ARPU +5-12% from matching features\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e23andMe: High‑margin kits \u0026amp; data =\u0026gt; $143M DTC, 12M genotyped, cash‑fueling R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAncestry reports and PGS kits are 23andMe cash cows: mature, high-margin products driving predictable revenue (~$143M DTC services 2024), \u0026gt;12M genotyped by 2025, ~62% kit gross margin (Q4 2025), ~70% N.A. market share, data licensing \u0026gt;70% gross margin, database spanning 4,500 regions; they fund R\u0026amp;D and health bets with low incremental cost.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC revenue 2024\u003c\/td\u003e\n\u003ctd\u003e$143M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenotyped customers 12\/2025\u003c\/td\u003e\n\u003ctd\u003e~12M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKit gross margin Q4 2025\u003c\/td\u003e\n\u003ctd\u003e~62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNA market share\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eData licensing gross margin\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003e23andMe BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact 23andMe BCG Matrix report you'll receive after purchase-no watermarks, no demo pages-just a fully formatted, analysis-ready document crafted for strategic clarity and professional presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIn-House Therapeutics Discovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe in-house therapeutics discovery arm was a high-cost, high-risk cash trap that 23andMe discontinued in late 2024 to curb ~$200M annual burn tied to R\u0026amp;D and clinical pipelines.\u003c\/p\u003e\n\u003cp\u003eDespite strong promise from its genetic database for target ID, multi-year timelines and no near-term revenue made internal development unsustainable.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 the company pivoted to out-licensing these assets, generating upfront and milestone payments to shore up liquidity and stabilize the balance sheet during restructuring.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Telehealth Services (Non-Genetic)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy telehealth services acquired via Lemonaid Health that do not integrate genetic data have failed to find a unique niche, operating in a saturated market where 23andMe's share is well below 1% of US virtual care visits (estimated \u0026lt;0.5% of 2024's ~1.2 billion telehealth encounters). \u003c\/p\u003e\n\u003cp\u003eWith US telehealth annual growth slowing to ~8% in 2024 and specialty, genetics-informed care growing faster, these legacy offerings show low growth prospects for 23andMe. \u003c\/p\u003e\n\u003cp\u003eManagement moved in 2024-2025 to wind down or divest non-core clinical services to refocus on genetics-informed care and higher-margin products; these units are prime divestiture candidates as the company streamlines the business model. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Expansion in Low-Interest Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e23andMe deprioritized expansion into markets with low consumer interest and high regulatory barriers, which showed low market share and limited growth versus North America and the UK; these regions consumed admin resources without clear profitability. By Q4 2025 the company narrowed geographic focus to high-ROI regions, reducing international operating expense by an estimated 12% year-over-year and reallocating budget to core markets where lifetime value (LTV) is ~3x higher.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysical Retail Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePhysical retail partnerships are a Dog: by 2024 retail sales fell below 15% of 23andMe kit volume as online direct sales and subscription health services grew; placement fees of 20-30% erode margins versus web-store sales where gross margin is ~65%.\u003c\/p\u003e\n\u003cp\u003eDuring the 2025 restructuring 23andMe cut expensive retail distribution, shifting marketing spend to digital acquisition, raising web conversion and reducing CAC by an estimated 18% year-over-year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRetail \u0026lt;15% of kit volume (2024)\u003c\/li\u003e\n\u003cli\u003ePlacement fees 20-30%\u003c\/li\u003e\n\u003cli\u003eWeb-store gross margin ~65%\u003c\/li\u003e\n\u003cli\u003eDigital CAC down ~18% post-2025 shift\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOne-Time Specialty Health Reports\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOne-time specialty health reports-stand-alone, non-subscription SKUs-have lost appeal as users favor 23andMe+ for bundled value; in 2025 23andMe reported subscription growth of 18% YoY while single-report purchases fell an estimated 25%.\u003c\/p\u003e\n\u003cp\u003eThese individual reports hold low portfolio share and generate negligible recurring revenue, contributing under 5% of 2024 consumer revenues per company filings; they fragment product strategy.\u003c\/p\u003e\n\u003cp\u003eManagement is consolidating offerings into membership tiers and phasing out isolated SKUs in favor of simplified subscription pricing to boost LTV and reduce churn.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSingle-report sales down ~25% (2024-25)\u003c\/li\u003e\n\u003cli\u003eSubscriptions +18% YoY (2025)\u003c\/li\u003e\n\u003cli\u003eOne-time SKUs \u0026lt;5% of consumer revenue (2024)\u003c\/li\u003e\n\u003cli\u003eShift to subscription to raise LTV, cut product complexity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCut dogs: divest low-growth retail \u0026amp; reports, pivot to subscriptions-boost margins \u0026amp; cut CAC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: low-growth, low-share units-retail distribution, legacy telehealth, and one-time reports-drag margins and cash flow; retail \u0026lt;15% kit volume (2024), placement fees 20-30%, web-store GM ~65%; subscriptions +18% YoY (2025) vs single-report sales -25%; divest\/wind-down and shift to subscription raised web conversion and cut CAC ~18%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024-25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail kit share\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlacement fees\u003c\/td\u003e\n\u003ctd\u003e20-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeb-store GM\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubscriptions YoY\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSingle-report sales\u003c\/td\u003e\n\u003ctd\u003e-25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAC reduction\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGLP-1 Weight Loss Membership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLaunched on the Lemonaid telehealth platform, 23andMe's GLP-1 weight-loss membership links prescription GLP-1s with genetic research to study drug response; GLP-1s grew ~200% in US prescriptions 2023-2024 and global market hit $20B in 2024.\u003c\/p\u003e\n\u003cp\u003eIn BCG terms this is a Question Mark: the GLP-1 market is high-growth but 23andMe's share is small versus telehealth leaders and pharma; Lemonaid rollout reached an estimated few thousand patients by Q3 2025.\u003c\/p\u003e\n\u003cp\u003e23andMe is investing to test whether its genetic edge can drive better outcomes and market share, but success needs heavy promotion, physician network expansion, and clinical infrastructure-estimated marketing and clinical build ~ $50-100M over 2 years to scale nationally.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWhole Genome Sequencing (WGS) for Consumers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs sequencing costs fell below $500 per genome by late 2024, 23andMe is piloting whole genome sequencing (WGS) for consumers, targeting a market projected to reach $12.2B by 2028 (CAGR ~13%); this is high growth but 23andMe holds low share versus clinical leaders like Illumina and BGI.\u003c\/p\u003e\n\u003cp\u003eWGS is a question mark: scaling needs heavy capex in labs and rising storage costs (raw WGS adds ~100-200 GB per genome), plus regulatory and QC investments; payback depends on consumers paying a premium-early pilots suggest willingness-to-pay around $200-400 above SNP tests.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenetics-Informed EHR Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e23andMe is building tools to push genetic reports into Electronic Health Records (EHR) for physicians, targeting the $34B precision medicine market forecasted by Grand View Research for 2025; clinical adoption is nascent for 23andMe with \u0026lt;5% provider penetration. \u003c\/p\u003e\n\u003cp\u003eThis shift needs enterprise sales, payer relationships, and HIPAA\/CLIA-level compliance-costly changes from DTC operations-raising regulatory and sales execution risk. \u003c\/p\u003e\n\u003cp\u003eIf uptake rises to mid-single-digit hospital systems by 2027, revenue could scale into tens of millions and the unit may become a star; today it remains a speculative question mark. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew Polygenic Risk Score (PRS) Reports\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003e23andMe is fast rolling out polygenic risk score reports for bipolar disorder and coronary artery disease into the preventive-health market, where global digital health is \u0026gt;$600B (2024) but clinical uptake for PRS remains limited-peer-reviewed utility evidence still under 10% for many conditions.\u003c\/p\u003e\n\u003cp\u003eThese PRS need continuous R\u0026amp;D to ensure accuracy across ancestries; 40-50% more diverse GWAS samples are needed per recent genomics analyses, raising annual program costs by an estimated $15-30M.\u003c\/p\u003e\n\u003cp\u003eManagement must choose: keep heavy, costly investment in specific PRS reports with uncertain short-term revenue, or reallocate to broader health modules that can scale faster and drive subscription retention.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowing market: preventive-health digital market \u0026gt;$600B (2024)\u003c\/li\u003e\n\u003cli\u003eClinical adoption: validated clinical utility \u0026lt;10% for many PRS\u003c\/li\u003e\n\u003cli\u003eDiversity gap: need 40-50% more diverse GWAS data\u003c\/li\u003e\n\u003cli\u003eEstimated R\u0026amp;D uplift: $15-30M\/year for inclusive PRS\u003c\/li\u003e\n\u003cli\u003eStrategic trade-off: niche PRS vs scalable health modules\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Research Partnerships (Post-GSK)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFollowing the end of the exclusive GSK deal in 2023, 23andMe is seeking new large-scale research partnerships with multiple biotech firms to regain momentum; this is a high-growth but currently rebuilding segment with under 10 active major deals versus 20+ during peak, per 2025 filings.\u003c\/p\u003e\n\u003cp\u003eThese partnerships can diversify revenue-historically research agreements generated about 30% of pipeline value-but 23andMe holds a smaller market share of active collaborations and must prove longitudinal cohort value to secure multi-year contracts.\u003c\/p\u003e\n\u003cp\u003eSuccess hinges on demonstrating longitudinal data utility: retention rates, repeat-sample consent (~65% in 2024), and linked health outcomes drive partner willingness to pay and convert the data asset into steady growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth potential; currently rebuilding after GSK exit\u003c\/li\u003e\n\u003cli\u003e\u0026lt;10 major active deals vs 20+ at peak (2025 filings)\u003c\/li\u003e\n\u003cli\u003eResearch revenue potential ~30% of pipeline value historically\u003c\/li\u003e\n\u003cli\u003eKey metric: 65% repeat-sample consent (2024)\u003c\/li\u003e\n\u003cli\u003eOutcome depends on proving longitudinal data value to partners\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e23andMe's big bets: high-cost scale-up into GLP‑1, WGS \u0026amp; PRS with uncertain payoff\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks: 23andMe targets high-growth GLP-1, WGS, PRS, and enterprise EHR markets but holds low share; scaling needs $65-150M capex\/marketing and regulatory spend (2025 est.), WGS storage ~150GB\/genome, GLP-1 pilot ~few thousand patients (Q3 2025), PRS utility \u0026lt;10%, repeat-sample consent 65% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eScaling spend\u003c\/td\u003e\n\u003ctd\u003e$65-150M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWGS storage\/genome\u003c\/td\u003e\n\u003ctd\u003e~150GB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGLP-1 pilot size\u003c\/td\u003e\n\u003ctd\u003efew thousand (Q3 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePRS utility\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepeat consent\u003c\/td\u003e\n\u003ctd\u003e65% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"BCG Matrix","offers":[{"title":"Default Title","offer_id":44508939649107,"sku":"23andme-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0709\/3102\/1907\/files\/23andme-bcg-matrix.webp?v=1776708418","url":"https:\/\/bcgmatrixtemplate.com\/products\/23andme-bcg-matrix","provider":"BCG Matrix","version":"1.0","type":"link"}